Calquence is under clinical development by AstraZeneca and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

Diagnosis. Monoclonal T-cell lymphoproliferative disorder, potentially induced by imatinib. Management. Imatinib was stopped, after which the tumor lesions spontaneously regressed and, eventually ...